Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.
Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, Burbury K, Turner G, Di Iulio J, Bressel M, Westerman D, Lade S, Dreyling M, Dawson SJ, Dawson MA, Seymour JF, Roberts AW. Tam CS, et al. Among authors: di iulio j. N Engl J Med. 2018 Mar 29;378(13):1211-1223. doi: 10.1056/NEJMoa1715519. N Engl J Med. 2018. PMID: 29590547 Free article. Clinical Trial.
Stem cell factor and high-dose twice daily filgrastim is an effective strategy for peripheral blood stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine: results of a Phase II study with an historical comparator.
Herbert KE, Morgan S, Prince HM, Westerman DA, Wolf MM, Carney DA, Yuen K, di Iulio J, Seymour JF. Herbert KE, et al. Among authors: di iulio j. Leukemia. 2009 Feb;23(2):305-12. doi: 10.1038/leu.2008.302. Epub 2008 Nov 6. Leukemia. 2009. PMID: 18987661 Clinical Trial.
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).
Iland HJ, Bradstock K, Supple SG, Catalano A, Collins M, Hertzberg M, Browett P, Grigg A, Firkin F, Hugman A, Reynolds J, Di Iulio J, Tiley C, Taylor K, Filshie R, Seldon M, Taper J, Szer J, Moore J, Bashford J, Seymour JF; Australasian Leukaemia and Lymphoma Group. Iland HJ, et al. Among authors: di iulio j. Blood. 2012 Aug 23;120(8):1570-80; quiz 1752. doi: 10.1182/blood-2012-02-410746. Epub 2012 Jun 19. Blood. 2012. PMID: 22715121 Free article. Clinical Trial.
A randomized trial of prophylactic palifermin on gastrointestinal toxicity after intensive induction therapy for acute myeloid leukaemia.
Bradstock KF, Link E, Collins M, Di Iulio J, Lewis ID, Schwarer A, Enno A, Marlton P, Hahn U, Szer J, Cull G, Seymour JF; Australasian Leukaemia and Lymphoma Group. Bradstock KF, et al. Among authors: di iulio j. Br J Haematol. 2014 Dec;167(5):618-25. doi: 10.1111/bjh.13086. Epub 2014 Aug 21. Br J Haematol. 2014. PMID: 25142189 Free article. Clinical Trial.
Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.
Iland HJ, Collins M, Bradstock K, Supple SG, Catalano A, Hertzberg M, Browett P, Grigg A, Firkin F, Campbell LJ, Hugman A, Reynolds J, Di Iulio J, Tiley C, Taylor K, Filshie R, Seldon M, Taper J, Szer J, Moore J, Bashford J, Seymour JF; Australasian Leukaemia and Lymphoma Group. Iland HJ, et al. Among authors: di iulio j. Lancet Haematol. 2015 Sep;2(9):e357-66. doi: 10.1016/S2352-3026(15)00115-5. Epub 2015 Aug 20. Lancet Haematol. 2015. PMID: 26685769 Clinical Trial.
Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia.
Bradstock KF, Link E, Di Iulio J, Szer J, Marlton P, Wei AH, Enno A, Schwarer A, Lewis ID, D'Rozario J, Coyle L, Cull G, Campbell P, Leahy MF, Hahn U, Cannell P, Tiley C, Lowenthal RM, Moore J, Cartwright K, Cunningham I, Taper J, Grigg A, Roberts AW, Benson W, Hertzberg M, Deveridge S, Rowlings P, Mills AK, Gill D, Bardy P, Campbell L, Seymour JF; Australasian Leukaemia & Lymphoma Group. Bradstock KF, et al. Among authors: di iulio j. J Clin Oncol. 2017 May 20;35(15):1678-1685. doi: 10.1200/JCO.2016.70.6374. Epub 2017 Apr 3. J Clin Oncol. 2017. PMID: 28368672 Clinical Trial.
Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions.
Handunnetti SM, Anderson MA, Burbury KI, Thompson PA, Burke G, Bressel M, Di Iulio JL, Hicks RJ, Westerman DA, Lade S, Pott C, Agarwal R, Koldej RM, Ritchie D, Dreyling M, Dawson MA, Dawson SJ, Seymour JF, Roberts AW, Tam CS. Handunnetti SM, et al. Among authors: di iulio jl. Blood. 2024 Apr 25:blood.2023023388. doi: 10.1182/blood.2023023388. Online ahead of print. Blood. 2024. PMID: 38662991
Prognostic features for response and survival in elderly patients with de novo acute myeloid leukemia treated with mitoxantrone and intermediate dose cytarabine.
Grigg AP, Reynolds J, McQuillan A, Juneja SK, Di Iulio J, Hui C, Smith C, Kimber R, Bradstock KF; Australasian Leukaemia and Lymphoma Group. Grigg AP, et al. Among authors: di iulio j. Leuk Lymphoma. 2005 Mar;46(3):367-75. doi: 10.1080/10428190400013076. Leuk Lymphoma. 2005. PMID: 15621826 Clinical Trial.
87 results